Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer.

Trial Profile

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs BC 819 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors BioCancell Therapeutics
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Results from this trial show that primary endpoint has been met and signs of efficacy observed at 240 mg dose. BioCancell is acting to expand the trial at highest dosage group.
    • 06 Feb 2012 Additional lead trial investigator (Ronnie Shapira-Frommer) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top